Strides Pharma Falls 11.60%: 4 Key Factors Driving the Weekly Decline

Monday, 19 January 2026: Mixed Technical Signals Amid Price Momentum Shift

Strides Pharma began the week under pressure, closing at Rs.869.40, down 3.47% from the previous Friday’s close of Rs.900.65. This decline came alongside a 0.49% drop in the Sensex, indicating the stock was underperforming the broader market. Technical analysis revealed a complex interplay of bullish and bearish signals, with the Moving Average Convergence Divergence (MACD) and momentum indicators suggesting a moderation in upward momentum. Despite a mildly bullish daily moving average, weekly and monthly charts showed cautionary signs, including mildly bearish MACD and mixed On-Balance Volume (OBV) trends. The stock’s Mojo Score was at 50.0, reflecting a Hold rating, signalling cautious optimism amid volatility.

Tuesday, 20 January 2026: Downgrade to Sell Amid Technical and Fundamental Concerns

The stock continued its downward trajectory, closing at Rs.860.30, a further 1.05% decline. This day was pivotal as MarketsMOJO downgraded Strides Pharma from a Hold to a Sell rating, citing deteriorating technical trends and fundamental weaknesses. The downgrade was driven by a shift to mildly bearish technical indicators, including MACD, KST, and Dow Theory assessments on weekly and monthly charts. Fundamental concerns included a modest average Return on Capital Employed (ROCE) of 7.27%, high Debt to EBITDA ratio of 6.58 times, and significant promoter share pledging at 44.13%. Despite positive quarterly earnings growth, these factors raised caution about the stock’s near-term outlook. The Mojo Score dropped to 34.0, reflecting increased risk and a less favourable market sentiment.

Wednesday, 21 January 2026: Continued Bearish Momentum and Volume Surge

On 21 January, Strides Pharma’s stock price fell sharply by 4.06% to close at Rs.825.35, marking the steepest daily decline of the week. This drop occurred amid a significant increase in trading volume to 13,419 shares, indicating heightened selling pressure. The stock’s technical indicators confirmed a shift to a mildly bearish stance, with MACD and KST oscillators signalling weakening momentum. The Relative Strength Index (RSI) remained neutral, suggesting no oversold conditions yet. The stock’s price remained well below its 52-week high of Rs.1,024.90, underscoring the ongoing correction phase. The Sensex declined by 0.47% on the same day, but Strides Pharma’s underperformance was more pronounced.

Thursday, 22 January 2026: Sharp Rebound on Heavy Volume

In a notable reversal, the stock surged 4.78% to close at Rs.864.80, supported by an extraordinary volume spike to 94,283 shares. This rebound contrasted with the Sensex’s 0.76% gain, indicating a strong recovery attempt by Strides Pharma. Technical indicators such as Bollinger Bands showed a mildly bullish bias on weekly and monthly scales, while daily moving averages remained supportive. This rally suggested short-term buying interest amid the broader downtrend, possibly driven by bargain hunting or technical short-covering. However, the stock remained below key moving averages, and the overall technical outlook stayed cautious given the preceding declines.

Friday, 23 January 2026: Intraday Low and Heavy Price Pressure Close the Week

The week ended on a weak note as Strides Pharma’s shares plunged 7.93% to Rs.796.20, hitting an intraday low of Rs.795. This decline was sharper than the Sensex’s 1.33% fall, highlighting significant stock-specific selling pressure. The stock traded below all major moving averages, including 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. The Pharmaceuticals & Biotechnology sector also faced pressure but to a lesser extent. The Mojo Score remained at 34.0 with a Sell rating, reflecting the deteriorated technical and fundamental outlook. This intraday low marked a critical support test, with the stock nearing its 52-week low of Rs.530.70, raising caution for investors.

Key Takeaways from the Week

1. Significant Underperformance: Strides Pharma’s 11.60% weekly decline starkly contrasts with the Sensex’s 3.31% fall, highlighting stock-specific weakness amid broader market volatility.

2. Technical Downgrade and Bearish Momentum: The downgrade from Hold to Sell by MarketsMOJO on 19 January 2026 was driven by deteriorating technical indicators including MACD, KST, and Dow Theory, signalling weakening price momentum and increased downside risk.

3. Fundamental Concerns Amid Positive Earnings: Despite strong quarterly earnings growth and operational performance, concerns over modest ROCE, high leverage (Debt/EBITDA 6.58x), and substantial promoter share pledging (44.13%) weigh on the stock’s outlook.

4. Volatile Trading and Price Pressure: The week saw a sharp rebound on 22 January followed by a steep decline on 23 January, with the stock trading below all major moving averages and hitting an intraday low near Rs.795, indicating sustained selling pressure and technical weakness.

Conclusion: A Week Marked by Volatility and Caution

Strides Pharma Science Ltd’s performance over the week reflects a challenging environment characterised by technical deterioration, fundamental concerns, and heightened volatility. The stock’s sharp declines and downgrade to a Sell rating underscore increased risk and caution among investors. While the company’s long-term track record of strong returns remains intact, the current technical and financial signals suggest a period of consolidation or correction may be underway. Monitoring key support levels and technical indicators will be crucial in assessing the stock’s near-term trajectory amid ongoing market uncertainties.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →